Research programme: TNF-alpha targeted Nanobodies - Ablynx
Latest Information Update: 22 Jun 2018
At a glance
- Originator Ablynx
- Class Antibodies; Proteins
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 19 Jun 2018 Ablynx has been acquired by Sanofi
- 16 Jul 2016 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Belgium (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (Parenteral)